Nuclear Medicine and Biology
Volume 37, Issue 2 , Pages 215-226 , February 2010

Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent

  • Domokos Máthé

      Affiliations

    • Department of Applied Radioisotopes and Animal Experimentation, National ‘Frédéric Joliot-Curie’ Institute of Radiobiology and Radiohygiene, H-1221 Budapest, Hungary
    • Corresponding Author InformationCorresponding author. Tel.: +36 1 482 2012; fax: +36 1 482 2007.
    • ,
  • Lajos Balogh

      Affiliations

    • Department of Applied Radioisotopes and Animal Experimentation, National ‘Frédéric Joliot-Curie’ Institute of Radiobiology and Radiohygiene, H-1221 Budapest, Hungary
    • ,
  • András Polyák

      Affiliations

    • Department of Applied Radioisotopes and Animal Experimentation, National ‘Frédéric Joliot-Curie’ Institute of Radiobiology and Radiohygiene, H-1221 Budapest, Hungary
    • ,
  • Réka Király

      Affiliations

    • Department of Applied Radioisotopes and Animal Experimentation, National ‘Frédéric Joliot-Curie’ Institute of Radiobiology and Radiohygiene, H-1221 Budapest, Hungary
    • ,
  • Teréz Márián

      Affiliations

    • Institute of Nuclear Medicine, Debrecen University, Debrecen, Hungary
    • ,
  • Dariusz Pawlak

      Affiliations

    • Institute of Atomic Energy, Radioisotope Centre POLATOM, Swierk-Otwock, Poland
    • ,
  • John J. Zaknun

      Affiliations

    • International Atomic Energy Agency (IAEA), Vienna, Austria
    • ,
  • Maroor R.A. Pillai

      Affiliations

    • International Atomic Energy Agency (IAEA), Vienna, Austria
    • ,
  • Győző A. Jánoki

      Affiliations

    • Department of Applied Radioisotopes and Animal Experimentation, National ‘Frédéric Joliot-Curie’ Institute of Radiobiology and Radiohygiene, H-1221 Budapest, Hungary

Received 14 May 2009 ,Revised 15 August 2009 ,Accepted 28 September 2009.

References 

  1. Mercadante S, Fulfaro F. Management of painful bone metastases. Curr Opin Oncol. 2007;19:308–314
  2. Cicek M, Oursler MJ. Breast cancer bone metastasis and current small therapeutics. Cancer Metastasis Rev. 2006;25:635–644
  3. Berenson JR, Rajdev L, Broder M. Managing bone complications of solid tumors. Cancer Biol Ther. 2006;9:1086–1089
  4. Macedo A, Araujo A, Carvalho Melo F, et al. Cost-effectiveness of samarium-153-EDTMP for the treatment of pain due to multiple bone metastases in hormone-refractory prostate cancer versus conventional pain therapy, in Portugal. Acta Med Port. 2006;19:421–426
  5. Knapp FF, Mirzadeh S, Beets AL, et al. Reactor produced radioisotopes from ORNL for bone pain palliation. Appl Radiat Isot. 1998;49:309–315
  6. Anderson MP, Wiseman AG, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of systemic irradiation in patients with osteosarcoma and skeletal metastases. J Clin Onc. 2002;20:189–196
  7. Bauman G, Charette M, Reid R, Sathya J. Radiopharmaceuticals for the palliation of painful bone metastasis—a systemic review. Radiother Oncol. 2005;75:258–270
  8. Liepe K, Runge R, Kotzerke J. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol. 2005;131:60–66
  9. Minutoli F, Herberg A, Spadaro P, et al. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast. Q J Nucl Med Mol Imaging. 2006;50:355–362
  10. Silberstein EB. Dosage and response in the radiopharmaceutical therapy of painful osseous metastases. J Nucl Med. 1996;37:249–252
  11. Srivastava S, Dadachova E. Recent advances in radionuclide therapy. Semin Nucl Med. 2001;31:330–341
  12. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6:392–400
  13. Hosain F, Spencer RP. Radiopharmaceuticals for palliation of metastatic osseous lesions: Biologic and physical background. Semin Nucl Med. 1992;22:11–16
  14. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004;45:1358–1365
  15. Sartor O. Overview of samarium Sm-153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol. 2004;6(Suppl 10):S3–S12
  16. Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer. 2007;109:637–643
  17. Coronado M, Redondo A, Coya J, et al. Clinical role of Sm-153-EDTMP in the treatment of painful bone metastatic disease. Clin Nucl Med. 2006;31:605–610
  18. Wang RF, Zhang CL, Zhu SL, Zhu M. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. Med Princ Pract. 2003;12:97–101
  19. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63:940–945
  20. Brenner W, Kampen WU, Kampen AM, Henze E. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. J Nucl Med. 2001;42:230–236
  21. Ogawa K, Mukai T, Asano D, et al. Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model. J Nucl Med. 2007;48:122–127
  22. Oh SJ, Won KS, Moon DH, et al. Preparation and biological evaluation of 188Re-ethylenediamine-N,N,N′,N′tetrakis(methylene phosphonic acid) as a potential agent for bone pain palliation. Nucl Med Commun. 2002;23:75–83
  23. Liepe K, Franke WG, Kropp J, Koch R, Runge R, Hliscs R. Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases. Nuklearmedizin. 2000;39:146–151
  24. Li S, Liu J, Zhang H, Tian M, Wang J, Zheng X. Rhenium-188 HEDP to treat painful bone metastases. Clin Nucl Med. 2001 Nov;26(11):919–922
  25. Pillai MRA, Chakraborty S, Das T, Venkatesh M, Ramamoorthy N. Production logistics of 177Lu for radionuclide therapy. Appl Radiat Isot. 2003;59:109–118
  26. Bernhardt P, Benjegård SA, Kölby L, et al. Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. Int J Rad Onc Biol Phys. 2001;51:514–524
  27. Syme AM, Kirkby C, Riauka TA, Fallone BG, McQuarrie SA. Monte Carlo investigation of single cell beta dosimetry for intraperitoneal radionuclide therapy. Phys Med Biol. 2004;49:1959–1972
  28. Ando A, Ando I, Tonami N, et al. 177Lu-EDTMP: a potential therapeutic bone agent. Nucl Med Comm. 1998;19:587–591
  29. Rutty Solá AG, Arguelles MG, Botazzini D, et al. Lutetium-177 EDTMP for bone pain palliation. Preparation, biodistribution and pre-clinical studies. Radiochim Acta. 2000;88:157–161
  30. Chakraborty S, Das T, Unni PR, et al. 177Lu-labeled polyaminophosphonates as potential agents for bone pain palliation. Nucl Med Commun. 2002;23:67–74
  31. Das T, Chakraborty S, Unni PR, Sarma HD, Samuel G, Banerjee S, et al. 177Lu labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl. Radiat. Isot. 2002;57:177–184
  32. Das T, Chakraborty S, Sarma HD, Banerjee S. 177Lu-DOTMP: a viable agent for palliative radiotherapy of painful bone metastasis. Radiochim Acta. 2008;96:55–61
  33. Chakraborty S, Das T, Banerjee S, Balogh L, Chaudhari PR, Sarma HD, et al. 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis.. Cancer Biother. Radiopharm. 2008;23:202–213
  34. Sagar VV, Piccone JM, Charkes ND. Studies of skeletal tracer kinetics: III. Tc-99m(Sn)methylenediphosphonate uptake in the canine tibia as a function of blood flow. J Nucl Med. 1979;20:1257–1261
  35. Kumar V, Kumar D, Howman-Giles RB, Little DG. Is 99mTc-labelled pamidronate a better agent than 99mTc-medronate for bone imaging?. Nucl Med Commun. 2007;28:101–107
  36. Toegel S, Hoffmann O, Wadsak W, et al. Uptake of bone-seekers is solely associated with mineralisation! A study with 99mTc-MDP, 153Sm-EDTMP and 18F-fluoride on osteoblasts. Eur J Nucl Med Mol Imaging. 2006;33:491–494
  37. Essman SC, Lewis MR, Miller WH. Intraorgan biodistribution and dosimetry of 153Sm-ethylenediaminetetramethylene phosphonate in juvenile rabbit tibia: implications for targeted radiotherapy of osteosarcoma. J Nucl Med. 2005;46:2076–2082
  38. Essman SC, Lattimer J, Cook JL, Turnquist S, Kuroki K. Effects of 153Sm-ethylenediaminetetramethylene phosphonate on physeal and articular cartilage in juvenile rabbits. J Nucl Med. 2003;44:1510–1515
  39. Eary JF, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med. 1993;34:1031–1036
  40. Brenner W, Kampen WU, Brummer C, von Forstner C, Zuhayra M, Czech N, et al. Bone uptake studies in rabbits before and after high-dose treatment with 153Sm-EDTMP or 186Re-HEDP. J Nucl Med. 2003;44:247–251

☆ Part of this work was conducted under an International Atomic Energy Agency (IAEA) Coordinated Research Project and a European Commission FP6 grant to the European Molecular Imaging Laboratories (LSH-CT 2004-503569).

PII: S0969-8051(09)00242-X

doi: 10.1016/j.nucmedbio.2009.09.004

Nuclear Medicine and Biology
Volume 37, Issue 2 , Pages 215-226 , February 2010

Article Tools

* Image Usage & Resolution